Methylated DNA Detect in Paraneoplastic Syndrome of Nervous System

Completed

Interventions: Other: Lung cancer
Other: Suspected lung cancer
Other: Positive methylated DNA

Brief Summary: The purpose of this study is to verify whether the cell-free DNA of lung cancer in the blood can be used as a biomarker for early diagnosis and prognosis evaluation of patient with paraneoplastic syndrome of the nervous system.

Detailed Description: Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible in the neuropathy. The disease is a rare clinical syndrome, and lung cancer is the most common type of tumor that causes PNS.If PNS can be diagnosed when there are no tumor symptoms, not only can the cause of PNS be identified, but early tumors can be found for treatment time, and measures can be taken in the early stages of the tumor to improve survival. Tumor free DNA (cell-free DNA, cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells. In normal cells, tumor suppressor genes are expressed and proto-oncogenes are silenced; in tumor cells, tumor suppressor genes are hypermethylated and silenced, and oncogenes are hypomethylated and activated. The release of free DNA into the blood will be quickly cleared in tens of minutes to several hours, which can reflect the body's cell damage in real time, and is of great significance for monitoring the early occurrence and development of the disease. At present, the sensitivity of lung cancer cf-DNA detection technology is close to 100%, and the specificity is 94%, which is an effective detection technology for early detection of lung cancer.

Recruitment & Eligibility

Inclusion Criteria

The agnogenic typical neurological syndromes (including encephalomyelitis, marginal encephalitis, subacute cerebellar degeneration, strabismus ocular clonic-myoclonus, subacute sensory neuron disease, Lambert-Eaton myasthenic syndrome, skin Myositis, etc.) patient who predisposed to a tumor.
Pathologically confirmed as lung cancer or suggested as lung cancer patient by imaging (pulmonary CT/Positron Emission Tomography-CT), tumor biomarkers, anti-brain tissue antibodies, etc.

Exclusion Criteria

Lacunar infarction
Aortic atherosclerotic cerebral infarction
Clear cardiogenic cerebral infarction
Other related system diseases (arteritis, vascular dissection, migraine and vasospasm, etc.)

Arm && Interventions

Group	Intervention	Description
Lung cancer with negative methylated DNA	Lung cancer	Blood DNA methylation abnormalities are not found in lung cancer.
Lung cancer with positive methylated DNA	Positive methylated DNA	Blood DNA methylation abnormalities are found in lung cancer.
Lung cancer with positive methylated DNA	Lung cancer	Blood DNA methylation abnormalities are found in lung cancer.
Suspected lung cancer with negative methylated DNA	Suspected lung cancer	Blood DNA methylation abnormalities are not found in suspected lung cancer.
Suspected lung cancer with positive methylated DNA	Suspected lung cancer	Blood DNA methylation abnormalities are found in suspected lung cancer.
Suspected lung cancer with positive methylated DNA	Positive methylated DNA	Blood DNA methylation abnormalities are found in suspected lung cancer.

Primary Outcome Measures

Name	Time	Method
Level of cf-DNA	1 year after recruitment	Tumor-free DNA (cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells.

Secondary Outcome Measures

Name	Time	Method
Incidence of lung cancer	1 year after recruitment	The rate of lung cancer occurence among all the inclusion patients
Survival time	1 years after recruitment	The time interval from disease diagnosis to death
Changes of mRS score	1 year after recruitment	Documentation in the medical record of a Modified Rankin Score (mRS). The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 5. A separate category of 6 is usually added for patients who expire. The Modified Rankin Score (mRS) is the most widely used outcome measure in stroke clinical trials. Standardized interviews to obtain a mRS score are recommended at 3 months (90 days) following hospital discharge.
1-year mortality rate	1 year after recruitment	The rate of death among all the inclusion patients after 1 year